Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334880 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorders With Hyperactivity, sponsored by New River Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT00334880: Completed Phase 3 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorders With Hyperactivity, sponsored by New River Pharmaceuticals.
NCT00334880 is a Phase 3 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorders With Hyperactivity that has completed, run by New River Pharmaceuticals. The registered enrollment target is 420 participants, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (98% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334880, a Phase 3 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorders With Hyperactivity, has completed, sponsored by New River Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).
Conditions Studied
Interventions
- DRUG NRP104
Study Locations (20)
California
- Valley Clinical Research, Inc. - El Centro
- University of California, Irvine Child Development Center - Irvine
- Bay Area Research Institute - Lafayette
- Peninsula Research Associates - Rolling Hills Estate
- University of California, San Francisco, Dept. of Psychiatry - San Francisco
- Encompass Clinical Research - Spring Valley
Florida
- Gulfcoast Clinical Research Center - Fort Myers
- Miami Research Associates - Miami
- Clinical Neuroscience Solutions, Inc. - Orlando
- Meridien Research - Tampa
- Janus Center for Psychiatric Research LLC - West Palm Beach
Connecticut
- Yale University School of Medicine - New Haven
- Psychiatric Medicine Center - New London
Georgia
- Northwest Behavioral Research Center - Roswell
- Carman Research - Smyrna
Kansas
- Psychiatric Associates - Overland Park
- Vince and Associates Clinical Research - Overland Park
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- Alpine Clinical Research Center - Boulder
Maryland
- Johns Hopkins at Green Spring Station - Lutherville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00334880 record still lists
NCT00334880 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (98% higher).
The record links to 3 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which NRP104 is the first listed.
NCT00334880 names 20 study sites across 8 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00334880 about?
NCT00334880 is a clinical study titled "Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)". The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).
What is the current status of trial NCT00334880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2006-05. Estimated completion is 2006-11.
What conditions does trial NCT00334880 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders.
What interventions are being tested in trial NCT00334880?
The interventions under investigation include: NRP104 (DRUG).
Who is sponsoring clinical trial NCT00334880?
This trial is sponsored by New River Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334880 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00334880's enrollment target sits among peer trials
420 12th of 102 higher than 91 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia